Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The growth of the metastatic castrate-resistant prostate cancer market is expected to be driven by the expected rising prevalence of prostate cancer cases due...
Erdafitinib has shown “durable efficacy” in patients with BCG-unresponsive, high-risk NMIBC with FGFR3 alterations, according to researchers. Erdafitinib has shown “durable efficacy” in patients with BCG-unresponsive, high-risk NMIBC with FGFR3 alterations, according to researchers.
If approved, V116 would offer significant improvements in safety and effectiveness for the prevention of pneumococcal disease.
In this article, we discuss the 13 most profitable pharmaceutical stocks to buy.
Twenty-six companies have concluded the first ever pilot of the four-day week in a developing country - and the first in Africa - which has produced some surprisingly successful results...